Backs FY23 revenue view $5.6B-$6B, consensus $5.78B.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
- Edwards Lifesciences options imply 5.3% move in share price post-earnings
- Edwards Lifesciences downgraded to Underperform from Outperform at Bernstein
- Edwards Lifesciences downgraded to Neutral from Overweight at Piper Sandler
- Edwards Lifesciences not reaffirming Q4, 2023 guidance